Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 113 | 2024 | 11126 | 5.670 |
Why?
|
Androgen Antagonists | 52 | 2024 | 1377 | 5.640 |
Why?
|
Phenylthiohydantoin | 26 | 2022 | 193 | 5.420 |
Why?
|
Androstenes | 21 | 2021 | 170 | 4.310 |
Why?
|
Receptors, Androgen | 37 | 2022 | 1058 | 4.150 |
Why?
|
Prostate-Specific Antigen | 62 | 2024 | 2494 | 4.020 |
Why?
|
Antineoplastic Agents, Hormonal | 35 | 2023 | 1524 | 3.600 |
Why?
|
Nitriles | 33 | 2023 | 955 | 2.900 |
Why?
|
Androstadienes | 10 | 2019 | 345 | 2.830 |
Why?
|
Taxoids | 26 | 2022 | 666 | 2.790 |
Why?
|
Neoadjuvant Therapy | 21 | 2024 | 2727 | 2.460 |
Why?
|
Benzamides | 26 | 2022 | 1379 | 2.230 |
Why?
|
Leuprolide | 11 | 2024 | 321 | 2.170 |
Why?
|
Prostatectomy | 23 | 2024 | 1890 | 2.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 48 | 2024 | 11525 | 1.930 |
Why?
|
Prednisone | 21 | 2024 | 1574 | 1.840 |
Why?
|
Androgens | 25 | 2024 | 1281 | 1.800 |
Why?
|
Antineoplastic Agents | 33 | 2022 | 13693 | 1.710 |
Why?
|
Benzimidazoles | 5 | 2019 | 850 | 1.660 |
Why?
|
Kallikreins | 8 | 2020 | 258 | 1.590 |
Why?
|
Neoplasm Metastasis | 36 | 2021 | 4851 | 1.500 |
Why?
|
Steroid 17-alpha-Hydroxylase | 7 | 2014 | 98 | 1.410 |
Why?
|
Neoplasms, Hormone-Dependent | 12 | 2014 | 415 | 1.370 |
Why?
|
Adenocarcinoma | 18 | 2022 | 6364 | 1.300 |
Why?
|
Neoplasm Recurrence, Local | 24 | 2024 | 9240 | 1.280 |
Why?
|
Radium | 2 | 2020 | 65 | 1.270 |
Why?
|
Drug Resistance, Neoplasm | 24 | 2021 | 5172 | 1.250 |
Why?
|
Germ-Line Mutation | 10 | 2022 | 1788 | 1.080 |
Why?
|
Bone Neoplasms | 12 | 2020 | 2530 | 0.920 |
Why?
|
Thiohydantoins | 2 | 2021 | 20 | 0.890 |
Why?
|
Genetic Counseling | 3 | 2023 | 600 | 0.890 |
Why?
|
Male | 191 | 2024 | 350115 | 0.870 |
Why?
|
Tosyl Compounds | 6 | 2018 | 113 | 0.780 |
Why?
|
Androgen Receptor Antagonists | 8 | 2022 | 114 | 0.760 |
Why?
|
Prostate | 13 | 2023 | 1775 | 0.720 |
Why?
|
Estramustine | 8 | 2013 | 35 | 0.700 |
Why?
|
Anilides | 7 | 2018 | 408 | 0.700 |
Why?
|
Treatment Outcome | 53 | 2024 | 63107 | 0.640 |
Why?
|
Ketoconazole | 5 | 2014 | 95 | 0.610 |
Why?
|
Urogenital Neoplasms | 1 | 2019 | 137 | 0.610 |
Why?
|
Aged | 94 | 2023 | 163288 | 0.610 |
Why?
|
Androstenols | 3 | 2013 | 25 | 0.610 |
Why?
|
Neoplastic Cells, Circulating | 5 | 2021 | 934 | 0.600 |
Why?
|
Azasteroids | 4 | 2014 | 38 | 0.600 |
Why?
|
Middle Aged | 94 | 2023 | 213390 | 0.570 |
Why?
|
Humans | 197 | 2024 | 744366 | 0.570 |
Why?
|
Organic Anion Transporters | 4 | 2019 | 100 | 0.540 |
Why?
|
DNA Repair | 3 | 2021 | 2046 | 0.500 |
Why?
|
Disease-Free Survival | 20 | 2022 | 6896 | 0.490 |
Why?
|
Video Recording | 1 | 2019 | 949 | 0.470 |
Why?
|
Neoplasm Staging | 21 | 2020 | 11031 | 0.460 |
Why?
|
Goserelin | 2 | 2013 | 129 | 0.460 |
Why?
|
Disease Progression | 27 | 2020 | 13286 | 0.420 |
Why?
|
Testosterone | 13 | 2024 | 2419 | 0.420 |
Why?
|
DNA Damage | 1 | 2021 | 2432 | 0.390 |
Why?
|
BRCA2 Protein | 4 | 2023 | 794 | 0.380 |
Why?
|
Urologic Neoplasms | 4 | 2016 | 318 | 0.370 |
Why?
|
Progesterone | 2 | 2014 | 775 | 0.370 |
Why?
|
Castration | 5 | 2024 | 159 | 0.360 |
Why?
|
Orchiectomy | 13 | 2015 | 474 | 0.340 |
Why?
|
Germ Cells | 3 | 2022 | 631 | 0.340 |
Why?
|
5-alpha Reductase Inhibitors | 3 | 2020 | 107 | 0.320 |
Why?
|
Hormone Antagonists | 1 | 2008 | 108 | 0.310 |
Why?
|
Combined Modality Therapy | 9 | 2021 | 8642 | 0.310 |
Why?
|
BRCA1 Protein | 3 | 2023 | 1149 | 0.300 |
Why?
|
Aged, 80 and over | 38 | 2021 | 57776 | 0.300 |
Why?
|
Urinary Bladder Neoplasms | 6 | 2020 | 2249 | 0.300 |
Why?
|
Biopsy | 7 | 2021 | 6755 | 0.300 |
Why?
|
Mifepristone | 1 | 2008 | 150 | 0.300 |
Why?
|
Radiography, Interventional | 1 | 2014 | 1095 | 0.290 |
Why?
|
Molecular Targeted Therapy | 4 | 2019 | 2725 | 0.290 |
Why?
|
Carcinoma | 5 | 2023 | 2375 | 0.290 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2022 | 3511 | 0.280 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2020 | 3480 | 0.280 |
Why?
|
Estrogens, Conjugated (USP) | 2 | 2023 | 275 | 0.270 |
Why?
|
Cancer Vaccines | 1 | 2013 | 1023 | 0.270 |
Why?
|
Survival Analysis | 17 | 2018 | 10252 | 0.270 |
Why?
|
Medical Oncology | 2 | 2018 | 2267 | 0.270 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2014 | 2016 | 0.270 |
Why?
|
Drug Administration Schedule | 9 | 2018 | 4933 | 0.270 |
Why?
|
Genetic Testing | 5 | 2022 | 3444 | 0.270 |
Why?
|
Chromogranins | 1 | 2005 | 160 | 0.250 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2022 | 841 | 0.240 |
Why?
|
Rho(D) Immune Globulin | 1 | 2003 | 34 | 0.240 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2023 | 50 | 0.240 |
Why?
|
Follow-Up Studies | 17 | 2020 | 39052 | 0.230 |
Why?
|
Carcinoma, Transitional Cell | 3 | 2015 | 808 | 0.220 |
Why?
|
Neoplasm, Residual | 2 | 2019 | 973 | 0.220 |
Why?
|
Urology | 2 | 2018 | 399 | 0.220 |
Why?
|
Genetic Predisposition to Disease | 5 | 2022 | 17446 | 0.220 |
Why?
|
3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2020 | 62 | 0.210 |
Why?
|
Hydrocortisone | 3 | 2009 | 1826 | 0.210 |
Why?
|
Prospective Studies | 13 | 2023 | 53290 | 0.210 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2023 | 1771 | 0.210 |
Why?
|
Prognosis | 17 | 2020 | 29060 | 0.200 |
Why?
|
Sequence Analysis | 1 | 2022 | 256 | 0.200 |
Why?
|
Mutation | 11 | 2022 | 29786 | 0.200 |
Why?
|
Retrospective Studies | 21 | 2023 | 77460 | 0.190 |
Why?
|
Salvage Therapy | 2 | 2023 | 1275 | 0.190 |
Why?
|
Gonadotropin-Releasing Hormone | 4 | 2017 | 1206 | 0.180 |
Why?
|
Enzyme Inhibitors | 1 | 2011 | 3799 | 0.180 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2020 | 3554 | 0.180 |
Why?
|
Dehydroepiandrosterone Sulfate | 3 | 2019 | 238 | 0.180 |
Why?
|
Risk Assessment | 10 | 2021 | 23336 | 0.180 |
Why?
|
Radioisotopes | 2 | 2023 | 500 | 0.180 |
Why?
|
Sesquiterpenes | 1 | 2020 | 177 | 0.180 |
Why?
|
Neuregulin-1 | 1 | 2020 | 142 | 0.170 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2003 | 233 | 0.170 |
Why?
|
Research Subjects | 1 | 2021 | 239 | 0.170 |
Why?
|
Paclitaxel | 3 | 2001 | 1708 | 0.170 |
Why?
|
Urothelium | 2 | 2011 | 277 | 0.170 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2003 | 652 | 0.170 |
Why?
|
DNA, Neoplasm | 3 | 2017 | 1758 | 0.160 |
Why?
|
Preoperative Period | 1 | 2021 | 550 | 0.160 |
Why?
|
Neoplasm Proteins | 3 | 2018 | 3707 | 0.160 |
Why?
|
Double-Blind Method | 9 | 2021 | 12025 | 0.160 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2018 | 91 | 0.160 |
Why?
|
Bone Marrow Neoplasms | 1 | 1999 | 104 | 0.160 |
Why?
|
Signal Transduction | 10 | 2022 | 23404 | 0.160 |
Why?
|
DNA Mismatch Repair | 2 | 2018 | 426 | 0.160 |
Why?
|
Time Factors | 14 | 2021 | 40075 | 0.160 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 7914 | 0.160 |
Why?
|
Vitis | 1 | 2017 | 18 | 0.160 |
Why?
|
Drug Therapy, Combination | 3 | 2021 | 6489 | 0.160 |
Why?
|
Gene Dosage | 3 | 2020 | 1252 | 0.150 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2022 | 332 | 0.150 |
Why?
|
Point Mutation | 3 | 2004 | 1624 | 0.150 |
Why?
|
Genes, BRCA2 | 1 | 2021 | 618 | 0.150 |
Why?
|
Maximum Tolerated Dose | 3 | 2015 | 892 | 0.150 |
Why?
|
Kaplan-Meier Estimate | 10 | 2020 | 6539 | 0.150 |
Why?
|
Retreatment | 2 | 2015 | 610 | 0.150 |
Why?
|
Survival Rate | 11 | 2020 | 12788 | 0.150 |
Why?
|
Gene Expression Profiling | 5 | 2021 | 9445 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2022 | 8432 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2020 | 578 | 0.140 |
Why?
|
Tissue Extracts | 1 | 2016 | 135 | 0.140 |
Why?
|
DNA Nucleotidylexotransferase | 1 | 1996 | 64 | 0.140 |
Why?
|
Cancer Care Facilities | 1 | 2019 | 402 | 0.140 |
Why?
|
Pain Perception | 1 | 2017 | 191 | 0.140 |
Why?
|
Neuroendocrine Tumors | 1 | 2022 | 594 | 0.130 |
Why?
|
Societies, Medical | 2 | 2018 | 3743 | 0.130 |
Why?
|
Immunotherapy | 3 | 2018 | 4446 | 0.130 |
Why?
|
Hormones | 3 | 2023 | 889 | 0.130 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2015 | 2110 | 0.130 |
Why?
|
3-Hydroxysteroid Dehydrogenases | 1 | 2014 | 34 | 0.130 |
Why?
|
Cell Line, Tumor | 8 | 2022 | 16690 | 0.130 |
Why?
|
Hydroxyprostaglandin Dehydrogenases | 1 | 2014 | 30 | 0.130 |
Why?
|
Paternal Exposure | 1 | 2015 | 89 | 0.130 |
Why?
|
Receptors, Glucocorticoid | 1 | 2017 | 302 | 0.130 |
Why?
|
Microsatellite Instability | 1 | 2018 | 684 | 0.130 |
Why?
|
Biological Transport | 2 | 2017 | 2120 | 0.130 |
Why?
|
Organoplatinum Compounds | 1 | 2016 | 408 | 0.120 |
Why?
|
Serine | 1 | 2018 | 826 | 0.120 |
Why?
|
United States | 14 | 2023 | 69872 | 0.120 |
Why?
|
Protein Isoforms | 1 | 2019 | 1730 | 0.120 |
Why?
|
Erythropoiesis | 1 | 2018 | 706 | 0.120 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2014 | 136 | 0.120 |
Why?
|
Multicenter Studies as Topic | 2 | 2017 | 1677 | 0.120 |
Why?
|
Anoikis | 1 | 2014 | 49 | 0.120 |
Why?
|
Plant Extracts | 1 | 2017 | 471 | 0.120 |
Why?
|
Erythropoietin | 1 | 2018 | 726 | 0.120 |
Why?
|
Repressor Proteins | 2 | 2024 | 3024 | 0.120 |
Why?
|
Patient Preference | 2 | 2018 | 889 | 0.120 |
Why?
|
Radiography | 5 | 2016 | 7023 | 0.110 |
Why?
|
Drug Therapy | 1 | 2016 | 497 | 0.110 |
Why?
|
Lutetium | 2 | 2023 | 32 | 0.110 |
Why?
|
Multivariate Analysis | 9 | 2022 | 12244 | 0.110 |
Why?
|
Radionuclide Imaging | 2 | 2014 | 2031 | 0.110 |
Why?
|
Protective Agents | 1 | 2014 | 156 | 0.110 |
Why?
|
Mice, SCID | 4 | 2020 | 2716 | 0.110 |
Why?
|
Heterocyclic Compounds, 1-Ring | 2 | 2023 | 65 | 0.110 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2017 | 1038 | 0.110 |
Why?
|
PTEN Phosphohydrolase | 2 | 2018 | 1142 | 0.110 |
Why?
|
Drugs, Investigational | 1 | 2014 | 214 | 0.110 |
Why?
|
Imidazolidines | 2 | 2005 | 39 | 0.110 |
Why?
|
Pyrimidines | 2 | 2015 | 2943 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 2 | 2022 | 1856 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2017 | 9955 | 0.100 |
Why?
|
Oncogenes | 1 | 2018 | 1265 | 0.100 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 277 | 0.100 |
Why?
|
Adult | 24 | 2021 | 214052 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2018 | 2938 | 0.100 |
Why?
|
Fluorine Radioisotopes | 1 | 2015 | 442 | 0.100 |
Why?
|
Sequence Analysis, DNA | 2 | 2021 | 4805 | 0.100 |
Why?
|
Decision Making | 2 | 2017 | 3888 | 0.100 |
Why?
|
Organic Anion Transporters, Sodium-Independent | 1 | 2011 | 24 | 0.100 |
Why?
|
Tumor Microenvironment | 2 | 2022 | 3590 | 0.100 |
Why?
|
Muscles | 2 | 2020 | 1614 | 0.100 |
Why?
|
Positron-Emission Tomography | 3 | 2022 | 6234 | 0.100 |
Why?
|
Quality of Life | 6 | 2017 | 12802 | 0.100 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2014 | 648 | 0.100 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 903 | 0.100 |
Why?
|
Glucocorticoids | 2 | 2018 | 2108 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2003 | 1968 | 0.100 |
Why?
|
Down-Regulation | 1 | 2018 | 3001 | 0.100 |
Why?
|
Dipeptides | 2 | 2023 | 409 | 0.090 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 2 | 2020 | 105 | 0.090 |
Why?
|
Cholestenone 5 alpha-Reductase | 1 | 2009 | 21 | 0.090 |
Why?
|
Nuclear Proteins | 2 | 2024 | 5856 | 0.090 |
Why?
|
Ureteral Neoplasms | 1 | 2011 | 111 | 0.090 |
Why?
|
Chromogranin A | 2 | 2008 | 54 | 0.090 |
Why?
|
Chromatography, Liquid | 1 | 2013 | 976 | 0.090 |
Why?
|
Pilot Projects | 3 | 2019 | 8319 | 0.090 |
Why?
|
Drug Approval | 1 | 2016 | 742 | 0.090 |
Why?
|
Testicular Neoplasms | 1 | 2015 | 806 | 0.090 |
Why?
|
Insulin Resistance | 1 | 2023 | 3864 | 0.080 |
Why?
|
DNA Helicases | 1 | 2014 | 861 | 0.080 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7721 | 0.080 |
Why?
|
Cystectomy | 1 | 2014 | 686 | 0.080 |
Why?
|
Genomics | 3 | 2022 | 5717 | 0.080 |
Why?
|
Practice Guidelines as Topic | 5 | 2020 | 7282 | 0.080 |
Why?
|
Immunohistochemistry | 6 | 2018 | 11366 | 0.080 |
Why?
|
Bone Marrow | 3 | 2005 | 2948 | 0.080 |
Why?
|
Nanotechnology | 1 | 2014 | 710 | 0.080 |
Why?
|
Carboplatin | 2 | 2008 | 801 | 0.080 |
Why?
|
Thiazoles | 1 | 2015 | 1483 | 0.080 |
Why?
|
DNA Mutational Analysis | 4 | 2017 | 4185 | 0.080 |
Why?
|
Radiopharmaceuticals | 2 | 2014 | 2645 | 0.070 |
Why?
|
Cisplatin | 3 | 2020 | 1662 | 0.070 |
Why?
|
Lymph Nodes | 2 | 2015 | 3476 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4839 | 0.070 |
Why?
|
Hyperaldosteronism | 1 | 2010 | 240 | 0.070 |
Why?
|
Internet | 1 | 2019 | 3056 | 0.070 |
Why?
|
Kidney Neoplasms | 2 | 2015 | 4262 | 0.070 |
Why?
|
Neoplasm Invasiveness | 2 | 2014 | 3616 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2015 | 2504 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 6 | 2019 | 35425 | 0.070 |
Why?
|
Predictive Value of Tests | 6 | 2021 | 15078 | 0.070 |
Why?
|
Angiogenesis Inhibitors | 2 | 2013 | 2038 | 0.070 |
Why?
|
Surgery, Computer-Assisted | 1 | 2014 | 1018 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2016 | 2417 | 0.070 |
Why?
|
Mass Spectrometry | 1 | 2013 | 2204 | 0.070 |
Why?
|
Epigenesis, Genetic | 4 | 2020 | 3646 | 0.070 |
Why?
|
Primary Health Care | 1 | 2022 | 4557 | 0.070 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1641 | 0.060 |
Why?
|
Consensus | 3 | 2022 | 2960 | 0.060 |
Why?
|
Models, Molecular | 1 | 2015 | 5451 | 0.060 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2011 | 2455 | 0.060 |
Why?
|
Sirolimus | 1 | 2012 | 1565 | 0.060 |
Why?
|
Intestinal Mucosa | 1 | 1996 | 3037 | 0.060 |
Why?
|
Alternative Splicing | 2 | 2021 | 1117 | 0.060 |
Why?
|
Pattern Recognition, Automated | 1 | 2011 | 1005 | 0.060 |
Why?
|
Flutamide | 3 | 1999 | 96 | 0.060 |
Why?
|
Sulfonamides | 1 | 2014 | 1940 | 0.060 |
Why?
|
Hemoglobinuria | 1 | 2003 | 13 | 0.060 |
Why?
|
Radiotherapy | 1 | 2011 | 1533 | 0.060 |
Why?
|
Osteoporosis | 1 | 2013 | 1579 | 0.060 |
Why?
|
Rh-Hr Blood-Group System | 1 | 2003 | 65 | 0.060 |
Why?
|
Patient Selection | 3 | 2023 | 4216 | 0.060 |
Why?
|
SEER Program | 2 | 2018 | 1507 | 0.060 |
Why?
|
Receptors, Estrogen | 2 | 2001 | 2190 | 0.060 |
Why?
|
Testis | 2 | 2017 | 804 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2020 | 7882 | 0.050 |
Why?
|
Neoplasms | 2 | 2022 | 21696 | 0.050 |
Why?
|
Risk | 3 | 2021 | 9688 | 0.050 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 504 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 3255 | 0.050 |
Why?
|
Cohort Studies | 6 | 2023 | 40559 | 0.050 |
Why?
|
Palliative Care | 3 | 2006 | 3493 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2022 | 3595 | 0.050 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2023 | 338 | 0.050 |
Why?
|
Risk Factors | 10 | 2020 | 72296 | 0.050 |
Why?
|
Mitoxantrone | 3 | 2006 | 152 | 0.050 |
Why?
|
Credentialing | 1 | 2022 | 126 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2022 | 288 | 0.050 |
Why?
|
Molecular Sequence Data | 3 | 2003 | 18111 | 0.050 |
Why?
|
Prostatic Diseases | 1 | 2001 | 56 | 0.050 |
Why?
|
Cell Line | 4 | 2022 | 16000 | 0.050 |
Why?
|
Remission Induction | 1 | 2006 | 2385 | 0.050 |
Why?
|
Adrenal Cortex | 1 | 2021 | 140 | 0.050 |
Why?
|
Cell Communication | 1 | 2008 | 1621 | 0.050 |
Why?
|
Polymerase Chain Reaction | 2 | 2003 | 6171 | 0.050 |
Why?
|
Gynecomastia | 1 | 2021 | 88 | 0.050 |
Why?
|
DNA-Binding Proteins | 2 | 2014 | 9647 | 0.050 |
Why?
|
Carcinoma, Renal Cell | 1 | 2015 | 3143 | 0.050 |
Why?
|
Phthalazines | 1 | 2022 | 363 | 0.050 |
Why?
|
MicroRNAs | 1 | 2016 | 3751 | 0.050 |
Why?
|
Estrogens | 1 | 2007 | 1566 | 0.040 |
Why?
|
Research Design | 1 | 2016 | 5984 | 0.040 |
Why?
|
Female | 15 | 2023 | 380193 | 0.040 |
Why?
|
Cyclin E | 1 | 2020 | 172 | 0.040 |
Why?
|
Animals | 11 | 2022 | 168768 | 0.040 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2021 | 315 | 0.040 |
Why?
|
Body Fat Distribution | 1 | 2021 | 244 | 0.040 |
Why?
|
Blood Proteins | 1 | 2004 | 1124 | 0.040 |
Why?
|
Steroid 16-alpha-Hydroxylase | 1 | 2018 | 12 | 0.040 |
Why?
|
Erythrocyte Transfusion | 1 | 2003 | 565 | 0.040 |
Why?
|
Mice | 7 | 2022 | 81201 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.040 |
Why?
|
Erythrocyte Count | 1 | 2018 | 163 | 0.040 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12356 | 0.040 |
Why?
|
Base Sequence | 2 | 2003 | 12797 | 0.040 |
Why?
|
Bone and Bones | 3 | 2015 | 2576 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 1996 | 10183 | 0.040 |
Why?
|
Mice, Inbred ICR | 1 | 2018 | 352 | 0.040 |
Why?
|
Glucuronides | 1 | 2017 | 20 | 0.040 |
Why?
|
Depression | 1 | 2017 | 7759 | 0.040 |
Why?
|
Cell Count | 1 | 2022 | 1856 | 0.040 |
Why?
|
Probability | 1 | 2003 | 2506 | 0.040 |
Why?
|
Spliceosomes | 1 | 2018 | 110 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2003 | 2971 | 0.040 |
Why?
|
Administration, Oral | 2 | 2016 | 3914 | 0.040 |
Why?
|
Dihydrotestosterone | 2 | 2013 | 190 | 0.040 |
Why?
|
Codon | 1 | 1999 | 611 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 705 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2008 | 4328 | 0.040 |
Why?
|
Cullin Proteins | 1 | 2018 | 181 | 0.040 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2018 | 257 | 0.040 |
Why?
|
Gene Duplication | 1 | 2018 | 329 | 0.040 |
Why?
|
Genes, myc | 1 | 2018 | 399 | 0.040 |
Why?
|
Testosterone Congeners | 1 | 2017 | 62 | 0.040 |
Why?
|
DNA Methylation | 2 | 2022 | 4285 | 0.040 |
Why?
|
Lipid Peroxidation | 1 | 2017 | 270 | 0.040 |
Why?
|
Genotype | 3 | 2017 | 12952 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2015 | 2924 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2017 | 15520 | 0.030 |
Why?
|
Sulfates | 1 | 2017 | 390 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2020 | 749 | 0.030 |
Why?
|
Drug Combinations | 1 | 2021 | 1958 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 713 | 0.030 |
Why?
|
Ferritins | 1 | 2018 | 590 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 2012 | 2887 | 0.030 |
Why?
|
Phenotype | 3 | 2018 | 16367 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2017 | 336 | 0.030 |
Why?
|
Diagnostic Imaging | 2 | 2023 | 3508 | 0.030 |
Why?
|
Alkaline Phosphatase | 1 | 2018 | 867 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2001 | 4751 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2015 | 20130 | 0.030 |
Why?
|
Superoxide Dismutase | 1 | 2017 | 596 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2018 | 671 | 0.030 |
Why?
|
Adrenal Glands | 1 | 2017 | 546 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 3 | 2018 | 5534 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2022 | 2216 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2018 | 2086 | 0.030 |
Why?
|
Androsterone | 1 | 2013 | 14 | 0.030 |
Why?
|
Filgrastim | 1 | 2014 | 133 | 0.030 |
Why?
|
Renal Dialysis | 1 | 2003 | 1783 | 0.030 |
Why?
|
Proteome | 1 | 2004 | 1798 | 0.030 |
Why?
|
Platinum | 1 | 2015 | 233 | 0.030 |
Why?
|
Pain Threshold | 1 | 2017 | 584 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2019 | 853 | 0.030 |
Why?
|
Bone Marrow Diseases | 1 | 1995 | 231 | 0.030 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 789 | 0.030 |
Why?
|
Drug Synergism | 1 | 2017 | 1794 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2018 | 1179 | 0.030 |
Why?
|
Registries | 2 | 2019 | 8091 | 0.030 |
Why?
|
Vinblastine | 1 | 2014 | 502 | 0.030 |
Why?
|
Hemoglobins | 1 | 2018 | 1532 | 0.030 |
Why?
|
Indazoles | 1 | 2014 | 290 | 0.030 |
Why?
|
History, 20th Century | 1 | 2020 | 2740 | 0.030 |
Why?
|
Haplotypes | 1 | 2018 | 2779 | 0.030 |
Why?
|
DNA, Complementary | 1 | 1995 | 2050 | 0.030 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2014 | 401 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2018 | 1340 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 1996 | 2505 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 1799 | 0.020 |
Why?
|
Spermatozoa | 1 | 2015 | 625 | 0.020 |
Why?
|
Platinum Compounds | 1 | 2011 | 96 | 0.020 |
Why?
|
Body Composition | 1 | 2021 | 2402 | 0.020 |
Why?
|
DNA Primers | 1 | 1996 | 2891 | 0.020 |
Why?
|
Estradiol | 2 | 1997 | 2020 | 0.020 |
Why?
|
Endonucleases | 1 | 2014 | 380 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1655 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 602 | 0.020 |
Why?
|
Pelvis | 1 | 2015 | 730 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2016 | 2184 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 14723 | 0.020 |
Why?
|
Canada | 1 | 2015 | 2065 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2949 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2022 | 13035 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 1996 | 1607 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2017 | 1988 | 0.020 |
Why?
|
Hypertension | 2 | 2021 | 8479 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2017 | 1837 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2018 | 3505 | 0.020 |
Why?
|
Genetic Loci | 1 | 2018 | 2575 | 0.020 |
Why?
|
Protozoan Infections | 1 | 1988 | 39 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2018 | 2418 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 1182 | 0.020 |
Why?
|
Proteins | 1 | 2023 | 6100 | 0.020 |
Why?
|
Cytokines | 1 | 2003 | 7323 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2020 | 5867 | 0.020 |
Why?
|
Intestinal Diseases, Parasitic | 1 | 1988 | 66 | 0.020 |
Why?
|
Pain | 2 | 2018 | 4988 | 0.020 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2008 | 135 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2234 | 0.020 |
Why?
|
Cell Cycle | 1 | 1996 | 2967 | 0.020 |
Why?
|
Methotrexate | 1 | 2014 | 1728 | 0.020 |
Why?
|
Cause of Death | 1 | 2018 | 3582 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4479 | 0.020 |
Why?
|
Disease Management | 1 | 2018 | 2460 | 0.020 |
Why?
|
Phosphorylation | 1 | 2018 | 8436 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 1995 | 6313 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2018 | 1796 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2016 | 4208 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 13991 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 895 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2014 | 2700 | 0.020 |
Why?
|
Pyridines | 1 | 2018 | 2825 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2010 | 10943 | 0.020 |
Why?
|
Bone Density Conservation Agents | 1 | 2013 | 772 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2019 | 3531 | 0.020 |
Why?
|
Regression Analysis | 1 | 2015 | 6459 | 0.020 |
Why?
|
Recurrence | 1 | 2017 | 8340 | 0.020 |
Why?
|
Treatment Failure | 1 | 2011 | 2618 | 0.020 |
Why?
|
Bone Marrow Examination | 1 | 2005 | 157 | 0.020 |
Why?
|
Quinazolines | 1 | 2011 | 1356 | 0.020 |
Why?
|
Models, Biological | 1 | 2001 | 9584 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 10483 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2020 | 19233 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2011 | 2373 | 0.020 |
Why?
|
Gene Expression | 1 | 2017 | 7798 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2014 | 6621 | 0.020 |
Why?
|
Cell Survival | 1 | 2014 | 5882 | 0.010 |
Why?
|
Piperidines | 1 | 2011 | 1602 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2015 | 8949 | 0.010 |
Why?
|
Software | 1 | 2017 | 4441 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 1986 | 527 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7730 | 0.010 |
Why?
|
Liver | 1 | 2018 | 7475 | 0.010 |
Why?
|
Protein Array Analysis | 1 | 2004 | 411 | 0.010 |
Why?
|
Serologic Tests | 1 | 2004 | 374 | 0.010 |
Why?
|
Immunochemistry | 1 | 2001 | 124 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8385 | 0.010 |
Why?
|
Models, Statistical | 1 | 2015 | 5101 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2017 | 4468 | 0.010 |
Why?
|
Estrogen Receptor beta | 1 | 2001 | 175 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15535 | 0.010 |
Why?
|
Colitis | 1 | 1988 | 1170 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2017 | 21748 | 0.010 |
Why?
|
Seizures | 1 | 2012 | 2859 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18373 | 0.010 |
Why?
|
Dexamethasone | 1 | 2006 | 1951 | 0.010 |
Why?
|
Transcription Factors | 1 | 2018 | 12207 | 0.010 |
Why?
|
Reference Values | 2 | 2001 | 4982 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 20952 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2017 | 18034 | 0.010 |
Why?
|
Androstenedione | 1 | 1997 | 131 | 0.010 |
Why?
|
Estrogen Receptor alpha | 1 | 2001 | 577 | 0.010 |
Why?
|
Pain Measurement | 1 | 2006 | 3420 | 0.010 |
Why?
|
beta-Galactosidase | 1 | 1997 | 574 | 0.010 |
Why?
|
Luciferases | 1 | 1997 | 733 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 3873 | 0.010 |
Why?
|
Infant | 1 | 2015 | 35134 | 0.010 |
Why?
|
Blotting, Western | 1 | 2001 | 5181 | 0.010 |
Why?
|
Genes, Reporter | 1 | 1997 | 1547 | 0.010 |
Why?
|
Child, Preschool | 1 | 2015 | 41005 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2011 | 19905 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 1997 | 1793 | 0.010 |
Why?
|
Imidazoles | 1 | 1997 | 1206 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2017 | 20824 | 0.010 |
Why?
|
Transfection | 1 | 1997 | 5895 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 1997 | 3773 | 0.010 |
Why?
|
Aging | 1 | 1986 | 8664 | 0.000 |
Why?
|
Radioimmunoassay | 1 | 1986 | 919 | 0.000 |
Why?
|